Important guidance for clients using GLP-1 and peptide therapies through VeyraRx™
GLP-1 receptor agonists (such as Semaglutide and Tirzepatide) carry a boxed warning regarding a potential risk of thyroid C-cell tumors. These medications are not recommended for individuals with:
Most side effects are mild and temporary, improving as your body adjusts to treatment. These may include:
Always inform your provider about all medications, supplements, and over-the-counter products you are using. GLP-1 and GIP medications may delay stomach emptying, which can affect how oral medications are absorbed. Your provider will help determine if timing adjustments are necessary.
VeyraRx™ therapies are prescribed under licensed provider supervision and compounded through U.S.-based 503A/503B pharmacies. The information above is provided for educational purposes and is not a substitute for medical care. Always follow your provider’s guidance and pharmacy instructions.
Stay updated on our promotions, news, and events! Sign up to receive our newsletter.